http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2561109-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9911c1ab8f7dd4cfbb513021437ab171 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0512b93febae3f947418ab53826c885 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-538 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cba7c519ba3e144704fd5ed5a7500bae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ce6c4795af448b7bd9b75d145d3f253 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d18a6481f89da6d0a24fbb079fb3e8f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b20238252cd7bb51180ef0d83c30d78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddbbdf70af5de921cd2fb730c2c436dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abb66f7a7e97c4555596f9ccbc048dae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7069c72f9175433f5ba578acad30fb5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dcba38cbc5a722ad09f47f2279e2902 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8414271f3e4d3425fe02592635463a93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10d838eaa2505b2298181390ae4a9f38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_185acb69785b58712564f258eb5d5aab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92532edf8569c6ace9b3c7f91fb88be0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f72ddf8663321a6dd3b3826fdcfb8052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c19902d565babb508ab0d664ba0d990 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_224ed2f3212daad5f89f94e494f00dad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8839ff8d27850b5281f02b9e5ad3744 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6720182550676a7675976632ac3d9342 |
| publicationDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2561109-C2 |
| titleOfInvention | Compounds and methods for using |
| abstract | FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound or its pharmaceutically acceptable salt; the compound is a) described by Formulawherein Ris absent; the index n means an integer from 0 to 2; when n = 0, then Xmeans -CH-; Xmeans a member specified in a group consisting of -CH-, -O-, -N(H)- and -N(R)-, wherein Ris specified in a group consisting of Calkyl; each X, Xand Xis independently specified in a group consisting of C(H); A means a member specified in a groupand(aa), wherein Ris independently specified in a group consisting of halogen and -R, wherein Ris specified in a group consisting of Calkyl; B means a member specified in a group of compoundsand(aaa), wherein Ris absent; L is absent or means a member specified in a group consisting of Carylene-Cheteroalkylene, Cheteroalkylene, Calkylene, Calkenylene, Calkynylene and -O-; heteroalkylene contains 1 or 2 heteroatoms specified in a group consisting of N, O or S; E means hydrogen or halogen; or alternatively, E is specified in a group consisting of phenyl, Cheteroaryl; Cheteroaryl is specified in a group consisting of pyrazol, pyridine and pyrazine, Cheterocycloalkyl; Cheterocycloalkyl is specified in a group consisting of morpholine, pyrrolidine, piperidine and piperazine, and Ccycloalkyl, and if so required 1 ring independently specified in a group consisting of a 5-merous heterocyclic ring containing 2 O heteroatoms, a benzene ring and a 5,6-merous heteroaromatic ring containing 2 N heteroatoms can be condensed with E; E and 1 ring condensed with E if so required are independently protected 0 to 5 times by substitutes Rspecified in a group consisting of halogen, -NRR, -OR, -C(O)OR, -NRC(O)OR, -S(O)R, -R, -R, =O, -Z-NRRand -ZR; Zmeans Calkylene; each Rand Rq are independently specified in hydrogen and Calkyl; Ris specified in a group consisting of Calkyl and phenyl; Ris specified in a group consisting of phenyl and pyrazole, and 1 pyrimidine ring can be condensed with R. Or the compound b) is specified in a group consisting of 2-(1-(benzo[d]thiazol-2-ylcarbamoyl)-1,2,3,4-tetrahydroquinolin-7-yl)-5-(4-methoxyphenyl)-N,N-dimethylthiazol-4-carboxamide, 2-(1-(benzo[d]thiazol-2-ylcarbamoyl)-1,2,3,4-tetrahydroquinolin-7-yl)-5-(4-fluorophenoxy)thiazol-4-carboxamide and N-(benzo[d]thiazol-2-yl)-6-(6-(methylsulphonylcarbamoyl)-5-(3-phenoxypropoxy)pyridin-2-yl)-2H-benzo[b][1,4]oxazine-4(3H)-carboxamide. The invention also refers to specific compounds. The compounds according to the inventions are applicable for a pharmaceutical composition having BCl-Xantiapoptosis protein inhibitory activity. The pharmaceutical composition contains a therapeutically effective amount of the composition of formula a) or b), or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable diluent, carrier or excipient.EFFECT: new compounds inhibiting BCl-Xantiapoptosis protein.21 cl, 2 tbl, 7 dwg, 66 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2799873-C2 |
| priorityDate | 2008-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1442.